Mankind Pharma has announced a strategic partnership with Innovent Biologics to introduce Sintilimab, a PD-1 immunotherapy, to the Indian market. This collaboration aims to enhance patient access to innovative cancer treatments in India.
Mankind Pharmais one of the leading pharmaceutical companies in India, known for its diverse portfolio of high-quality medicines. Established in 1995, the company has grown rapidly and is now one of the top players in the Indian pharmaceutical industry. The company focuses on providing affordable healthcare solutions in multiple therapeutic areas, including antibiotics, gastrointestinal disorders, dermatology, cardiovascular health, and more.
Innovent Biologics is a leading biopharmaceutical company based in China, primarily focused on the development, manufacturing, and commercialization of innovative biologic medicines for the treatment of cancer, autoimmune diseases, and other major diseases. Founded in 2011, it aims to address unmet medical needs by developing high-quality and affordable therapies that improve patients’ lives. Innovent specializes in oncology, immunology, and other therapeutic areas, with a strong emphasis on monoclonal antibodies (mAbs) and immune-oncology treatments. The company has developed several groundbreaking biologic drugs. One of its most notable products is Sintilimab (TYVYT), a PD-1 monoclonal antibody that has been approved in China for the treatment of multiple types of cancer, including non-small cell lung cancer (NSCLC), liver cancer, gastric cancer, and Hodgkin’s lymphoma.The company has a robust pipeline of biologic candidates across various stages of clinical development, with a focus on immuno-oncology and other innovative biologics that address unmet medical needs.While Innovent started in China, it has gradually expanded its focus to international markets and aims to provide innovative therapies to patients around the world.
How does the collaboration aim to improve cancer care in India?
Under this partnership, Mankind Pharma will manage the registration, import, marketing, and distribution of Sintilimab in India. Innovent will handle the manufacturing and supply aspects. This collaboration aims to address critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region. Cancer has become a major health concern in India, with its burden projected to reach 29.8 million Disability-Adjusted Life Years (DALYs) by 2025. The introduction of Sintilimab is expected to provide a significant treatment option for patients battling various types of cancer. This partnership marks a significant step in enhancing oncology care in India, offering patients access to advanced immunotherapy treatments that have shown promising results in other markets.
